File size: 3,317 Bytes
c9d0ebc
65e3518
c9d0ebc
d2058b2
88b3ddf
 
 
 
d2058b2
75e6a8b
 
 
d2058b2
 
 
 
 
 
88b3ddf
d2058b2
75e6a8b
 
 
d2058b2
88b3ddf
 
75e6a8b
 
 
 
88b3ddf
 
 
 
d2058b2
c9d0ebc
 
75e6a8b
 
d2058b2
88b3ddf
d2058b2
 
 
 
 
 
88b3ddf
d2058b2
 
 
 
 
 
75e6a8b
c9d0ebc
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
PRIMO is an open benchmark, and it is **deliberately incomplete**. The **Boards**
page shows exactly how far it reaches today, the live boards, and names the
gaps as open cards. Everything past that still needs somebody to bring it.

PRIMO was started by **Scienta Lab**. The intent is community governance; how
that actually works is part of what the first partners will define.

## Add a cohort

PRIMO has no shortage of models. What is hard to find is **an omics cohort with
patient-level clinical labels**, whether that is drug response, a severity score
or a molecular subtype. If you hold one, or know a group that does, tell us:

- **modality** and roughly how many patients
- **what is labelled**, and how many patients carry that label
- **disease and tissue**
- **licence**, and whether the data can be redistributed

[Propose a cohort](mailto:karim.elkanbi@scientalab.com?subject=PRIMO%20cohort%20proposal&body=Modality%20and%20rough%20patient%20count%3A%0A%0AWhat%20is%20labelled%2C%20and%20how%20many%20patients%20carry%20that%20label%3A%0A%0ADisease%20and%20tissue%3A%0A%0ALicence%2C%20and%20whether%20the%20data%20can%20be%20redistributed%3A%0A)

There is no formal acceptance process yet. We are writing it with the first
partners, and we would rather admit that than invent rules nobody has agreed to.
What you will get today is a real answer and a technical conversation.

## Add a task, without bringing any data

This one costs you nothing but an idea. Ask **a better question of the cohorts
already here**: a label we are not predicting, a transfer split nobody has tried,
or a metric that would say more than the one we use. Methodology counts here as
much as data does.

[Propose a task](mailto:karim.elkanbi@scientalab.com?subject=PRIMO%20task%20proposal&body=Task%20I%20would%20add%3A%0A%0AWhich%20cohorts%20already%20in%20PRIMO%20it%20uses%3A%0A%0AWhat%20is%20predicted%2C%20and%20with%20which%20metric%3A%0A%0AWhy%20it%20says%20something%20the%20current%20tasks%20do%20not%3A%0A)

## Add a modality or a therapeutic area

The **OPEN** cards on the Boards page mark the omics layers and clinical areas
PRIMO does not reach yet. Read them as gaps waiting for someone rather than as a roadmap we
are already working through. Opening one takes a single cohort with clinical
labels, and not a whole atlas.

[Claim an open board](mailto:karim.elkanbi@scientalab.com?subject=PRIMO%20open%20board&body=Board%20I%20want%20to%20open%3A%0A%0AWhat%20I%20can%20bring%20%28cohort%2C%20labels%2C%20licence%29%3A%0A)

## Become a founding partner

Founding partners shape PRIMO rather than just appear on it: a voice on the
methodology, co-signature on what we publish, and early access to the results.

[Talk to us about partnership](mailto:karim.elkanbi@scientalab.com?subject=PRIMO%20founding%20partner&body=Organisation%3A%0A%0AWhat%20we%20would%20bring%20to%20PRIMO%3A%0A%0AWhat%20we%20would%20want%20from%20it%3A%0A)
· [primomics.org](http://primomics.org/)

## Smaller ways in

- **Question the method.** Open a thread in the Space's **Community** tab.
- **Submit a model.** Baselines are on the leaderboard already; beat them.
- **Read the paper**: [OpenReview](https://openreview.net/forum?id=v2SA8gHwqo)
- **Look at the data**: [PRIMOmics/primo](https://huggingface.co/datasets/PRIMOmics/primo)